Tonix Pharmaceuticals Holding Corp.
TNXP Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$5.17
KIRA · Stoqly’s AI analyst, in plain words
- Tonix Pharmaceuticals Holding Corp. had $13.1M of revenue in fiscal 2025, up 29.8% on the year before.
- Its operating margin was −959.1%, up 395.2 pts: of every 100 in sales, about −959 is left after running the business.
- Tonix Pharmaceuticals Holding Corp. lost $124M in fiscal 2025.
- Free cash flow was −$103M in fiscal 2025, −787.5% of revenue.
- Tonix Pharmaceuticals Holding Corp. returned $13.8M to shareholders in fiscal 2025. The diluted share count rose 1,056.0%.
Market cap
$86.0M
P/E
—
Revenue
$13.1M
Net income
−$124M
Free cash flow
−$103M
Operating margin
−959.1%
Tonix Pharmaceuticals Holding Corp. in 30 seconds · fiscal 2025
Are sales growing?
+29.8%
Yes. Sales grew 29.8% last year.
Does it make a profit?
−946.2%
No. It lost money last year.
Does profit turn into cash?
−787.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Tonix Pharmaceuticals Holding Corp. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Tonix Pharmaceuticals Holding Corp.
- CIK
- 0001430306
Tonix Pharmaceuticals Holding Corp. · TNXP
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $7.8M | $10.1M | $13.1M |
| Revenue growth | — | — | — | 29.9% | 29.8% |
| Gross margin | — | — | 39.0% | 23.1% | 49.3% |
| Operating margin | — | — | −1,523.9% | −1,354.3% | −959.1% |
| Net income | −$92.3M | −$110M | −$117M | −$130M | −$124M |
| Net margin | — | — | −1,501.8% | −1,288.3% | −946.2% |
| Diluted EPS | −$8.10 | −$20.01 | −$14,720.25 | −$176.60 | −$14.57 |
| Cash | |||||
| Cash from operations | −$75.6M | −$98.1M | −$102M | −$60.9M | −$99.8M |
| Capital expenditure | $35.3M | $48.1M | $7.9M | $0.1M | $3.4M |
| Free cash flow | −$111M | −$146M | −$110M | −$61.0M | −$103M |
| FCF margin | — | — | −1,414.8% | −604.8% | −787.5% |
| Share buybacks | — | — | $14.0M | — | $13.8M |
| Share count change | −88.0% | −48.7% | −99.9% | 9,220.3% | 1,056.0% |
| Debt and strength | |||||
| Cash and short-term investments | $179M | $120M | $24.9M | $98.8M | $208M |
| Debt incl. finance leases | — | — | $11.0M | $8.7M | — |
| Shareholders' equity | $219M | $207M | $106M | $140M | $245M |
| Current ratio | 8.7x | 7.2x | 2.5x | 6.5x | 7.4x |
| Interest coverage | — | — | — | −110.8x | −1,412.4x |
| Returns and quality | |||||
| Return on capital | — | — | −102.1% | −218.5% | — |
| Return on equity | −60.2% | −51.8% | −74.6% | −106.1% | −64.5% |
| Return on tangible equity | −42.2% | −56.4% | −123.0% | −93.3% | −50.6% |
| Piotroski F-score | — | — | — | 4 | 4 |
| Altman Z'' | 7.5 | 4.9 | −14.3 | −9.9 | −0.4 |
Insiders bought, 12 months
$0.5M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Tonix Pharmaceuticals Holding Corp. · TNXP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $5.17 a share, the company is worth $86.0M.
Source: SEC EDGAR XBRL filings (CIK 0001430306). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.